MedPath

Ezabenlimab

Generic Name
Ezabenlimab
Drug Type
Biotech
CAS Number
2249882-54-8
Unique Ingredient Identifier
5V1UI86573
Clinical Trials
Related News

A Study to Test BI 765179 Alone and in Combination With Ezabenlimab in Patients With Advanced Cancer (Solid Tumors) and BI 765179 in Combination With Pembrolizumab in Patients With Advanced Head and Neck Cancer

Phase 1
Recruiting
Conditions
Neoplasms
Interventions
First Posted Date
2021-07-12
Last Posted Date
2025-05-14
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
160
Registration Number
NCT04958239
Locations
🇲🇽

Hospital Universitario Dr Jose Eleuterio Gonzalez, Monterrey, Mexico

🇺🇸

The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States

🇺🇸

University of Arizona, Tucson, Arizona, United States

and more 44 locations

A Study Evaluating Different Doses of BI 765049 When Given Alone and When Given With Ezabenlimab to Patients With Advanced Solid Tumors Expressing the Protein B7-H6 on the Cell Surface

Phase 1
Completed
Conditions
Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung, Pancreatic Neoplasms, Carcinoma, Hepatocellular, Head and Neck Neoplasms, Gastrointestinal Neoplasms
Interventions
First Posted Date
2021-02-12
Last Posted Date
2025-01-10
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
67
Registration Number
NCT04752215
Locations
🇺🇸

MD Anderson Cancer Center Orlando, Orlando, Florida, United States

🇺🇸

University of Alabama at Birmingham, Birmingham, Alabama, United States

🇺🇸

Valkyrie Clinical Trials, Los Angeles, California, United States

and more 11 locations

A Study to Test Different Doses of BI 765063 Alone and in Combination With BI 754091 in Japanese Patients With Different Types of Advanced Cancer (Solid Tumors)

Phase 1
Completed
Conditions
Solid Tumors
Interventions
First Posted Date
2020-12-04
Last Posted Date
2022-05-10
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
18
Registration Number
NCT04653142
Locations
🇯🇵

National Cancer Center Hospital East, Chiba, Kashiwa, Japan

🇯🇵

National Cancer Center Hospital, Tokyo, Chuo-ku, Japan

🇯🇵

Shikoku Cancer Center, Ehime, Matsuyama, Japan

and more 1 locations

A Study to Test BI 754091 Alone or in Combination With BI 836880 in People Who Have Advanced Anal Cancer

Phase 2
Withdrawn
Conditions
Anal Canal Squamous Cell Carcinoma
Interventions
First Posted Date
2020-08-05
Last Posted Date
2021-11-15
Lead Sponsor
Boehringer Ingelheim
Registration Number
NCT04499352
Locations
🇰🇷

Asan Medical Center, Seoul, Korea, Republic of

A Study to Find the Best Dose of BI 1387446 Alone or in Combination With Ezabenlimab (BI 754091) in Patients With Different Types of Advanced or Metastatic Cancer (Solid Tumors)

Phase 1
Completed
Conditions
Neoplasms
Interventions
First Posted Date
2019-11-01
Last Posted Date
2024-11-15
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
39
Registration Number
NCT04147234
Locations
🇪🇸

Hospital Vall d'Hebron-Barcelona-47683, Barcelona, Spain

🇺🇸

Froedtert and The Medical College of Wisconsin, Milwaukee, Wisconsin, United States

🇪🇸

CIO Clara Campal, Madrid, Spain

and more 4 locations

Phase 1b Study to Evaluate ATP128, VSV-GP128 and BI 754091, in Patients With Stage IV Colorectal Cancer

Phase 1
Active, not recruiting
Conditions
Stage IV Colon Cancer
Liver Metastasis Colon Cancer
Colorectal Cancer
MSS
Stage IV Rectal Cancer
Metastatic Colorectal Cancer
Interventions
First Posted Date
2019-08-06
Last Posted Date
2025-01-29
Lead Sponsor
Amal Therapeutics
Target Recruit Count
96
Registration Number
NCT04046445
Locations
🇺🇸

University of Texas, MD Anderson Cancer Center, Houston, Texas, United States

🇨🇭

University Hospital Zurich, Zürich, Zurich, Switzerland

🇧🇪

University Hospital Antwerpen, Edegem, Belgium

and more 9 locations

A Trial of BI 765063 Monotherapy and in Combination With BI 754091 in Patients With Advanced Solid Tumours

Phase 1
Active, not recruiting
Conditions
Solid Tumor, Adult
Interventions
First Posted Date
2019-06-18
Last Posted Date
2023-09-13
Lead Sponsor
OSE Immunotherapeutics
Target Recruit Count
116
Registration Number
NCT03990233
Locations
🇧🇪

Institut Jules Bordet, Brussels, Belgium

🇧🇪

Universitair Ziekenhuis Brussel, Brussel, Belgium

🇫🇷

Hospital St Pierre, La Réunion, France

and more 5 locations

A Study to Find the Best Dose of BI 836880 Alone and in Combination With BI 754091 in Japanese Patients With Different Types of Advanced Cancer

Phase 1
Completed
Conditions
Neoplasms
Interventions
First Posted Date
2019-06-03
Last Posted Date
2022-04-22
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
21
Registration Number
NCT03972150
Locations
🇯🇵

Shizuoka Cancer Center, Shizuoka, Sunto-gun, Japan

🇯🇵

National Cancer Center Hospital, Tokyo, Chuo-ku, Japan

A Study in Patients With Different Types of Advanced Cancer (Solid Tumors) to Test Different Doses of BI 907828 (Brigimadlin) in Combination With BI 754091 (Ezabenlimab) and BI 754111 or BI 907828 (Brigimadlin) in Combination With BI 754091 (Ezabenlimab)

Phase 1
Active, not recruiting
Conditions
Neoplasms
Interventions
First Posted Date
2019-05-28
Last Posted Date
2025-04-30
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
120
Registration Number
NCT03964233
Locations
🇫🇷

INS Bergonie, Bordeaux, France

🇫🇷

CTR Leon Berard, Lyon, France

🇫🇷

INS Gustave Roussy, Villejuif, France

and more 20 locations

This Study Tests How BI 754111 is Distributed in Patients With Advanced Non-small Cell Lung Cancer or Patients With Head and Neck Cancer Who Are Treated With BI 754091

Phase 1
Terminated
Conditions
Carcinoma, Non-Small-Cell Lung
Head and Neck Neoplasms
Interventions
First Posted Date
2018-12-19
Last Posted Date
2021-11-05
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
8
Registration Number
NCT03780725
Locations
🇳🇱

Amsterdam UMC Locatie VUMC, Amsterdam, Netherlands

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy